Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that Arun Upadhyay, PhD, Chief Scientific Officer and Head of Research & Development, will speak at the International Society for Cell & …
Ocugen’s Chief Scientific Officer to Present at International Cell & Gene Therapy Meeting Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on innovative therapies, announced the completion of dosing in the second cohort of its groundbreaking GARDian clinical trial for …
Ocugen Advances with Phase 1/2 Trial for Stargardt Disease Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on gene therapies for eye diseases, reported its first-quarter financial results for 2024 and provided an update on its …
Ocugen Advances Gene Therapy Trials, Targets 2026 for Key Regulatory Approvals Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) recently revealed a novel approach to shareholder incentives by declaring a dividend of Series C Preferred Stock. For every share of common stock …
Ocugen Announces Unique Dividend Strategy with Series C Preferred Stock Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), announced that its leadership will present at two notable life sciences conferences in New York. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will …
Ocugen to Highlight Clinical Developments at Upcoming Life Sciences Conferences Read More MALVERN, PA — Biopharmaceutical firm Ocugen, Inc. (NASDAQ: OCGN), today revealed that its Chief Scientific Officer and Head of Research & Development, Arun Upadhyay, PhD, is slated to speak at …
Ocugen to Spotlight Groundbreaking Retinal Disease Therapy at Retina World Congress Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, announced that Dr. Benjamin Bakall will present findings from the OCU400 Phase 1/2 clinical trials at the upcoming Retinal Cell …
Ocugen to Present Pioneering Gene Therapy Data at Retinal Innovation Summit Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) is poised to make a significant impact at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle, WA, …
Ocugen to Spotlight Groundbreaking Gene Therapy Research at ARVO 2024 Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in the development of a groundbreaking treatment for geographic atrophy (GA), an advanced form of dry age-related macular …
Ocugen Advances in Revolutionary Gene Therapy for Age-Related Macular Degeneration Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that its Chairman, CEO, and Co-Founder, Dr. Shankar Musunuri, will engage in a fireside chat at the Emerging Growth Virtual Healthcare …
Ocugen CEO to Highlight Gene Therapy Advances at Healthcare Equity Conference Read More